Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Written2017-05Aurelia Meloni-Ehrig
CSI Laboratories, Alpharetta, GA, USA;

Abstract Review on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), with data on clinics, and the genes involved.

Keywords Blastic Plasmacytoid Dendritic Cell Neoplas; Del(5q),; del(12p); del(13q); TET2; ZRSR2; TP53; ASXL1, CDKN1B; RB1; CDKN2A; CDKN2B; IKZF1; KMT2A

(Note : for Links provided by Atlas : click)


ICD-Topo C420,C421,C424
ICD-Morpho 9727/3 Blastic plasmacytoid dendritic cell neoplasm
Atlas_Id 2146

Clinics and Pathology

Phenotype / cell stem origin Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic neoplasm. Despite its rarity, there is extensive historic and scientific literature. Since 1994, when this neoplasm was first described (Adachi et al., 1994), BPDCN has been known with various names, including agranular CD4+ natural killer (NK) leukemia, CD4+/CD56+ hematodermic neoplasm, and blastic NK lymphoma (Facchetti et al., 2009; Pilichowska et al., 2007; Petrella et al., 2005; Assaf et al., 2007). In 2008, the WHO has placed this neoplasm in the category of acute myeloid leukemia (AML) and related precursor neoplasms (Facchetti et al., 2008; Swerdlow et al., 2008) following the realization that BPDCN results from the clonal proliferation of immature plasmacytoid dendritic cells (PDC) (Facchetti et al., 2008). In normal situations, the PDC are an essential part of the innate adaptive immunoresponse (Jegalian et al., 2009; Reizis et al., 2011). These cells respond to viral and bacterial infection by producing alpha-interferon. As such, they are also known also as alpha-interferon producing cells or plasmacytoid monocytes. Expansion of the normal PDCs can occur in autoimmune disorders, as well as Hodgkin lymphoma, and various carcinomas. Flow cytometry and immunohistochemistry studies have revealed that the neoplastic PDC of virtually all patients are typically found in the CD45dim blast gate region and are phenotypically defined by the co-expression of CD4, CD56, and CD123, absence of CD34, and lack of specific myeloid-, T-, B-, or NK-lineage markers (Pagano et al., 2013). Very rarely CD56 might not be expressed. In those cases, the expression of CD4, CD123, and TCL1 would be sufficient to suspect BPDCN (Herling et al., 2003). Approximately 50% of the cases might also express CD43, CD45RA, and CD68. Other markers observed less frequently include CD7, HLA-DR, TCL1, CD33, BDCA2/CD303, BDCA4/CD304, CLA, and MxA (Petrella et al., 2004; Pilichowska et al., 2007).
Epidemiology BPDCN is quite rare; less than 100 cases have been reported so far. The disease does not have a geographic predilection as it has been observed in various countries around the world (Tsagarakis et al., 2010; Qayoom et al., 2015; Assaf et al., 2007). The exact incidence might be difficult to determine due to the various definitions of BPDCN as a leukemia or a skin lymphoma prior to the 2008 WHO inclusion of this neoplasm into the AML and related precursors neoplasms (Facchetti et al., 2008). Recent reports in the incidence, indicate that this neoplasm accounts for 0.4% of all hematologic neoplasms, 0.7% of the primary cutaneous lymphomas, and less than 1% of all acute leukemias (Facchetti et al., 2008; Riaz et al., 2014; Rossi et al., 2006; Pagano et al., 2013). BPDCN has been described in all age groups, but is most common in adults; the majority of patients are older adults and the median age at diagnosis is 65 years. Some patients are younger than 40 years old, and even children with this neoplasm have been reported. The male to female ratio is 3:1.
Clinics The first symptom in most patients with BPDCN is the presence of multiple cutaneous lesions, often detected incidentally by dermatologists (Gera et al., 2014). As such, histologic diagnosis is required to distinguish BPDCN from other primary skin lesions or other leukemias and lymphomas characterized by cutaneous involvement (Gera et al., 2014). At the same time, or soon after, involvement of bone marrow and/or peripheral blood occurs. This involvement is thought to occur in approximately 90% of the cases. Lymph nodes might also be involved (approximately 50% of the cases). Overt leukemia is a common feature of BPDC during progression or relapse, often with a myelomonocytic phenotype, and is nearly always present in the terminal stage of the disease. However, a minority of patients (5-10% of cases) do not have cutaneous lesions, but present with a very aggressive (fulminant) leukemia (Wang et al., 2012; Rauh et al., 2012; Qayoom et al., 2015). In addition to the typically sites of involvement, other unusual sites might be also affected. Paluri et al. (2015) reported a patient diagnosed with a BPDCN confined to the sinonasal region and central nervous system (CNS). Although CNS is not typically considered a common site of involvement for BPDCN, a recent study has reported a frequent CNS involvement in their group of patients suggesting that the CNS might be a safe reservoir of blast cells in patients with leukemic presentation, due to the fact that drugs are unable to cross the blood-brain barrier (Martin-Martin et al., 2016). Regardless of the presentation, the overall prognosis for patients with BPDCN is unfavorable, with a median overall survival of approximately one year (Facchetti et al., 2008; Julia et al., 2013). In children, BPDCN is characterized by less frequent cutaneous involvement and a significant response to intensive acute lymphoblastic leukemia (ALL)-type chemotherapy, allowing patients to reach complete remission. The overall prognosis and long-term survival in pediatric patients is better than in adults. Some reports made the suggestion that childhood BPDCN might represent a different neoplasm than the one seen in adults (Jegalian et al., 2010; Rossi et al., 2006).
Cytology Examination of BPDCN patients with skin presentation reveals that the neoplasm involves the entire dermis and may extend to the subcutis, but not the epidermis (Gera et al., 2014. When the bone marrow is affected, there is a variable degree of involvement with variable dysplasia. The lymph nodes show a diffuse interfollicular and medullary involvement. Microscopic examination of the skin biopsy typically shows a diffuse monotonous infiltrate of intermediate-sized blast cells with round to oval nuclei and nucleoli, and scant agranular cytoplasm that resemble myeloid blasts, but with NK cell lineage differentiation (Ferreira et al., 2016; Ru et al., 2014). Intracytoplasmic microvacuoles are present in the majority of cases (Ferreira et al., 2016). The mitotic activity is variable.
Immunohistologic studies on lymph node sections show reactivity for CD56 and CD43 and lack reactivity for CD45 and TdT (original magnification ×375). Image available at Blastic plasmacytoid dendritic cell neoplasm. website. Accessed April 30th, 2017
(A) Lymph node biopsy. Monomorphous infiltrate of medium-sized cells with scant cytoplasm, round nuclear contours, finely granular chromatin, and numerous mitotic figures (hematoxylin-eosin, original magnification ×375); (B) Bone marrow core biopsy specimen. Hypercellular marrow with trilineage hematopoiesis and an interstitial infiltrate of immature blast-like cells (hematoxylin-eosin, original magnification ×375). (C) Peripheral blood smear after bone marrow transplantation. Immature blasts with high nuclear-to-cytoplasmic ratio, agranular cytoplasm, and round nuclear contours (Wright-Giemsa, original magnification ×500). Image available at Blastic plasmacytoid dendritic cell neoplasm. website. Accessed April 30th, 2017
Prognosis BPDCNA is an aggressive neoplasm with a median survival of approximately 12 months and typically poor response to chemotherapy (Facchetti et al., 2008; Julia et al., 2013). Patients with the leukemic form of the neoplasm have a shorter survival (approximately 8 months) (Riaz et al., 2014). Since skin presentation occurs in the majority of patients, the first therapeutic approach is targeted to treat the skin lesions. There is no specific induction therapy designed specifically to treat this neoplasm. Patients have been treated with existing therapies typically used for non-Hodgkin lymphoma, AML, and ALL (Falcone et al., 2016). Various AML and ALL therapeutic protocols have been used. The AML protocol consists of variable combinations of cytarabine, etoposide, idarubicin, anthracycline, fludarabine, and filgrastim, whereas the ALL protocol includes variable combinations of cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, prednisone, asparaginase, and CHOP with and without etoposide (Pagano et al., 2013). Approximately 90% of patients seem to respond initially to these therapies, but the disease later recurs in the majority of patients (Bayerl et al., 2002). However, Voelkl et al. (2011) reported an elderly patient with BPDCN with AML presentation and skin lesions who achieved a 26 month long remission after treatment with dose intensive multiagent chemotherapy. Long lasting remissions might occur in pediatric patients with good response to acute leukemia chemotherapy and allogeneic stem cell transplantation (Paluri et al., 2015; Male et al., 2010). Several studies have demonstrated that allogeneic stem cell transplantation following a reduced intensity conditioning (avoidance of high-dose therapy) offers the best chance for long lasting remission, particularly when performed during the first complete remission, and suggests that this form of therapy should be pursued aggressively for all BPDCN patients (Dietrich et al. 2011; Roos-Weil et al., 2013; Aoki et al., 2015). There are also clinical trials presently being conducted that are showing promising results. One of these trials consists in the administration of a single cycle of therapy of SL-401. This is a recombinant human interleukin 3a protein conjugated with truncated diphtheria a-toxin DT388-IL3, a potent inhibitor of protein synthesis (Stemline Therapeutics) (Frankel et al., 2014; Fitzgerald et al., 2014). The other clinical trial consists of a targeted therapy against CD56+ tumors. The drug in in this case is lorvotuzumab mertansine, which has been used to targets other hematologic neoplasms that express CD56 (Whiteman et al., 2014).


Cytogenetics Morphological An interesting fact about BPDCN is that the chromosome abnormalities are more similar to those that have been observed in high-grade myelodysplasia (MDS) and AML with MDS-related changes than those that have been described in lymphoma. Karyotypes are usually are complex like those that have also been described in therapy related MDS/AML, and are often hypodiploid. Recurrent deletions, some leading to loss of specific gene, have been identified by both conventional cytogenetics and array comparative genomic hybridization (aCGH) (Leroux et al., 2002; Oiso et al., 2012; Lucioni et al., 2011; Dijkman et al., 2007). The most common deletions are those involving 5q (72% of cases), 12p13.1-p13.2/ CDKN1B (64%), 13q13.1-14.2/ RB1 (64%), 6q (50%), 15q (43%), 9p21.3/ CDKN2A/ CDKN2B (28%), and 7p12.2/ IKZF1. Among these, the biallelic loss of 9p21.3 suggests a more aggressive course. In addition, three cases of MLL rearrangement, two with t(11;19)(q23;p13.3) KMT2A/ MLLT1 and one with a 3-way t(4;9;11)(q12;p22;q23) have been reported in 3 patients aged 8, 42, and 50 years old, respectively (Leung et al., 2006; Toya et al., 2012; Yang et al. 2015). The involvement of MLL and the other recurrent chromosome abnormalities observed in BPDCN might pose a challenge for differentiating PBDCN from MDS, AML, or ALL since some of the abnormalities seen in PBDCN are common to these neoplasms. Therefore, authors urge careful evaluation of suspected cases of BPDCN and encourage the use of plasmacytoid dendritic cell markers to ensure that the blasts have no expression of myeloid or monocytic markers (particularly cases with MLL rearrangements), as well as perform extensive immunohistochemical and genetic analyses before definitively considering the diagnosis of BPDCN (Lee et al., 2016). In contrast, it is relatively easier to genetically differentiate BPDCN from NK neoplasms, since BPDCN does not have rearrangements of heavy chain, light chain, or T-cell receptor genes.
  G-banded karyotype of a patient with BPDCN: 44,XY,del(5)(q15q33),del(6)(q13q23),add(9)(p13),add(12)(p11.2),-13,-15, add(17)(p12). Hypodiploidy with deletions of 5q, 6q, 9p, 12p, and 17p is a common finding. Typically these karyotypes also show loss of chromosome 13 and 15, as seen in this case.

Genes involved and Proteins

Note In addition to the loss of tumor suppressor genes due to the various chromosome deletions mentioned in the cytogenetic section (i.e., CDKN1B, RB1, CDKN2A/CDKN2B, and IKZF1), several mutations involving oncogenes have been described. The most common are TET2 at 4q24 (57%), ZRSR2 at Xp22.2 (57%), TP53 at 17p13.2 (14%), and ASXL1 at 20q11.2 (Jardin et al., 2011; Alayed et al., 2013). Exome sequencing has also revealed mutations of other less common genes such as IKZF3 at 17q12, HOXB9at 17q21.3, UBE2G2 at 21q22.3 and ZEB2 at 2q22.3 (Menezes et al., 2014). Furthermore, some patients were found to have a FLT3-ITD mutation (Pagano et al. 2013).


High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma
Adachi M, Maeda K, Takekawa M, Hinoda Y, Imai K, Sugiyama S, Yachi A
Am J Hematol 1994 Dec;47(4):278-82
PMID 7526680
TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow
Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, Pemmaraju N, Zhang L, Shaikh AA, Aladily TN, Jain N, Luthra R, Medeiros LJ, Khoury JD
Am J Hematol 2013 Dec;88(12):1055-61
PMID 23940084
Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm
Aoki T, Suzuki R, Kuwatsuka Y, Kako S, Fujimoto K, Taguchi J, Kondo T, Ohata K, Ito T, Kamoda Y, Fukuda T, Ichinohe T, Takeuchi K, Izutsu K, Suzumiya J
Blood 2015 Jun 4;125(23):3559-62
PMID 25918345
CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer
Assaf C, Gellrich S, Whittaker S, Robson A, Cerroni L, Massone C, Kerl H, Rose C, Chott A, Chimenti S, Hallermann C, Petrella T, Wechsler J, Bagot M, Hummel M, Bullani-Kerl K, Bekkenk MW, Kempf W, Meijer CJ, Willemze R, Sterry W
J Clin Pathol 2007 Sep;60(9):981-9
PMID 17018683
Blastic natural killer cell lymphoma/leukemia: a report of seven cases
Bayerl MG, Rakozy CK, Mohamed AN, Vo TD, Long M, Eilender D, Palutke M
Am J Clin Pathol 2002 Jan;117(1):41-50
PMID 11789729
Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity
Dietrich S, Andrulis M, Hegenbart U, Schmitt T, Bellos F, Martens UM, Meissner J, Krämer A, Ho AD, Dreger P
Biol Blood Marrow Transplant 2011 Aug;17(8):1250-4
PMID 21215813
Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities
Dijkman R, van Doorn R, Szuhai K, Willemze R, Vermeer MH, Tensen CP
Blood 2007 Feb 15;109(4):1720-7
PMID 17068154
Neoplasms derived from plasmacytoid dendritic cells
Facchetti F, Cigognetti M, Fisogni S, Rossi G, Lonardi S, Vermi W
Mod Pathol 2016 Feb;29(2):98-111
PMID 26743477
A critical review of treatment modalities for blastic plasmacytoid dendritic cell neoplasm
Falcone U, Sibai H, Deotare U
Crit Rev Oncol Hematol 2016 Nov;107:156-162
PMID 27823644
Cytomorphological features of blastic plasmacytoid dendritic cell neoplasm on FNA and cerebrospinal fluid cytology: A review of 6 cases
Ferreira J, Gasparinho MG, Fonseca R
Cancer Cytopathol 2016 Mar;124(3):196-202
PMID 26618304
Targeted diphtheria toxin to treat BPDCN
FitzGerald DJ
Blood 2014 Jul 17;124(3):310-2
PMID 25035145
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients
Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E
Blood 2014 Jul 17;124(3):385-92
PMID 24859366
Blastic plasmacytoid dendritic cell neoplasm: evolving insights in an aggressive hematopoietic malignancy with a predilection of skin involvement
Gera S, Dekmezian MS, Duvic M, Tschen JA, Vega F, Cho-Vega JH
Am J Dermatopathol 2014 Mar;36(3):244-51
PMID 24247574
TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin
Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D
Blood 2003 Jun 15;101(12):5007-9
PMID 12576313
TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm
Jardin F, Ruminy P, Parmentier F, Troussard X, Vaida I, Stamatoullas A, Leprêtre S, Penther D, Duval AB, Picquenot JM, Courville P, Capiod JC, Tilly H, Bastard C, Marolleau JP
Br J Haematol 2011 May;153(3):413-6
PMID 21275969
Plasmacytoid dendritic cells: physiologic roles and pathologic states
Jegalian AG, Facchetti F, Jaffe ES
Adv Anat Pathol 2009 Nov;16(6):392-404
PMID 19851130
Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients
Julia F, Petrella T, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, Dereure O, Wetterwald M, d'Incan M, Grange F, Cornillon J, Tertian G, Maubec E, Saiag P, Barete S, Templier I, Aubin F, Dalle S
Br J Dermatol 2013 Sep;169(3):579-86
PMID 23646868
Acute Myeloid Leukemia With MLL Rearrangement and CD4+/CD56+ Expression can be Misdiagnosed as Blastic Plasmacytoid Dendritic Cell Neoplasm: Two Case Reports
Lee JM, Kim IS, Lee JN, Park SH, Kim HH, Chang CL, Lee EY, Kim HR, Oh SH, Song SA
Ann Lab Med 2016 Sep;36(5):494-7
PMID 27374717
CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique
Leroux D, Mugneret F, Callanan M, Radford-Weiss I, Dastugue N, Feuillard J, Le Mée F, Plessis G, Talmant P, Gachard N, Uettwiller F, Pages MP, Mozziconacci MJ, Eclache V, Sibille C, Avet-Loiseau H, Lafage-Pochitaloff M
Blood 2002 Jun 1;99(11):4154-9
PMID 12010820
CD4+/CD56+ hematologic malignancy with rearranged MLL gene
Leung R, Chow EE, Au WY, Chow C, Kwong YL, Lin SY, Ma ES, Wan TS, Wong KF
Hum Pathol 2006 Feb;37(2):247-9
PMID 16426929
Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21
Lucioni M, Novara F, Fiandrino G, Riboni R, Fanoni D, Arra M, Venegoni L, Nicola M, Dallera E, Arcaini L, Onida F, Vezzoli P, Travaglino E, Boveri E, Zuffardi O, Paulli M, Berti E
3 deletion Blood
PMID 21900200
Blastic plasmacytoid dendritic cell neoplasm should be treated with acute leukemia type induction chemotherapy and allogeneic stem cell transplantation in first remission
Male HJ, Davis MB, McGuirk JP, Abhyankar S, Aljitawi OS, Zhang D, Ganguly S
Int J Hematol 2010 Sep;92(2):398-400
PMID 20697854
Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy
Martín-Martín L, Almeida J, Pomares H, González-Barca E, Bravo P, Giménez T, Heras C, Queizán JA, Pérez-Ceballos E, Martínez V, Alonso N, Calvo C, lvarez R, Caballero MD, Orfao A
Oncotarget 2016 Mar 1;7(9):10174-81
PMID 26840087
Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm
Menezes J, Acquadro F, Wiseman M, Gómez-López G, Salgado RN, Talavera-Casañas JG, Buño I, Cervera JV, Montes-Moreno S, Hernández-Rivas JM, Ayala R, Calasanz MJ, Larrayoz MJ, Brichs LF, Gonzalez-Vicent M, Pisano DG, Piris MA, lvarez S, Cigudosa JC
Leukemia 2014 Apr;28(4):823-9
PMID 24072100
Loss of genomic DNA copy numbers in the p18, p16, p27 and RB loci in blastic plasmacytoid dendritic cell neoplasm
Oiso N, Tatsumi Y, Arao T, Rai S, Kimura M, Nakamura S, Itoh T, Nishio K, Matsumura I, Kawada A
Eur J Dermatol 2012 May-Jun;22(3):393-4
PMID 22361914
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study
Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, Lunghi M, Pica G, Onida F, Cattaneo C, Piccaluga PP, Di Bona E, Todisco E, Musto P, Spadea A, D'Arco A, Pileri S, Leone G, Amadori S, Facchetti F; GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute Leukemia Working Party)
Haematologica 2013 Feb;98(2):239-46
PMID 23065521
Unique presentation of blastic plasmacytoid dendritic cell neoplasm: a single-center experience and literature review
Paluri R, Nabell L, Borak S, Peker D
Hematol Oncol 2015 Dec;33(4):206-11
PMID 24850172
TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis
Petrella T, Meijer CJ, Dalac S, Willemze R, Maynadié M, Machet L, Casasnovas O, Vergier B, Teitell MA
Am J Clin Pathol 2004 Aug;122(2):307-13
PMID 15323148
CD4+/CD56+ hematodermic neoplasm ("blastic natural killer cell lymphoma"): neoplastic cells express the immature dendritic cell marker BDCA-2 and produce interferon
Pilichowska ME, Fleming MD, Pinkus JL, Pinkus GS
Am J Clin Pathol 2007 Sep;128(3):445-53
PMID 17709319
Blastic plasmacytoid dendritic cell neoplasm presenting as leukemia without cutaneous involvement in a 25 years male patient: Unusual presentation of a rare entity
Qayoom S, Durga G, George S, Rahman K
Indian J Pathol Microbiol 2015 Jul-Sep;58(3):377-80
PMID 26275271
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: Case series and literature review
Rauh MJ, Rahman F, Good D, Silverman J, Brennan MK, Dimov N, Liesveld J, Ryan DH, Burack WR, Bennett JM
Leuk Res 2012 Jan;36(1):81-6
PMID 21890199
Plasmacytoid dendritic cells: recent progress and open questions
Reizis B, Bunin A, Ghosh HS, Lewis KL, Sisirak V
Annu Rev Immunol 2011;29:163-83
PMID 21219184
Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy
Riaz W, Zhang L, Horna P, Sokol L
Cancer Control 2014 Oct;21(4):279-89
PMID 25310209
Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation
Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, Iriondo Atienza A, Arcese W, Beelen DW, Cornelissen JJ, Kröger N, Milone G, Rossi G, Jardin F, Peters C, Rocha V, Sureda A, Mohty M, Dreger P; European Group for Blood and Marrow Transplantation Lymphoma, Pediatric Diseases, and Acute Leukemia Working Parties
Blood 2013 Jan 17;121(3):440-6
PMID 23203822
Acute leukemia of dendritic cell lineage in childhood: incidence, biological characteristics and outcome
Rossi JG, Felice MS, Bernasconi AR, Ribas AE, Gallego MS, Somardzic AE, Alfaro EM, Alonso CN
Leuk Lymphoma 2006 Apr;47(4):715-25
PMID 16690531
Morphologic characteristics of blastic plasmacytoid dendritic cell neoplasm: a case report
Ru Y, Zhang P, Dong S, Wang H, Zhao S, Mi Y, Eyden B
Ultrastruct Pathol 2014 Feb;38(1):66-8
PMID 23957370
WHO classification of Tumors of Haematopoietic and Lymphoid Tissues
Swerdlow SH, Campo E, Harris NL, et al.
ARC Press, Lyon; 2008
The first case of blastic plasmacytoid dendritic cell neoplasm with MLL-ENL rearrangement
Toya T, Nishimoto N, Koya J, Nakagawa M, Nakamura F, Kandabashi K, Yamamoto G, Nannya Y, Ichikawa M, Kurokawa M
Leuk Res 2012 Jan;36(1):117-8
PMID 21831428
Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group
Tsagarakis NJ, Kentrou NA, Papadimitriou KA, Pagoni M, Kokkini G, Papadaki H, Pappa V, Marinakis T, Anagnostopoulos NI, Vadikolia C, Anagnostopoulos A, Angelopoulou MK, Terpos E, Poziopoulos C, Anargyrou K, Rontogianni D, Papadaki T, Psarra A, Kontopidou FN, Skoumi D, Papadhimitriou SI, Paterakis G; Hellenic Dendritic Cell Leukemia Study Group
Leuk Res 2010 Apr;34(4):438-46
PMID 19793612
Blastic plasmacytoid dendritic cell neoplasm with acute myeloid leukemia successfully treated to a remission currently of 26 months duration
Voelkl A, Flaig M, Roehnisch T, Alpay N, Schmidmaier R, Oduncu F
Leuk Res 2011 Jun;35(6):e61-3
PMID 21167600
Blastic plasmacytoid dendritic cell neoplasm without cutaneous lesion at presentation: case report and literature review
Wang H, Cao J, Hong X
Acta Haematol 2012;127(2):124-7
PMID 22236870
Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models
Whiteman KR, Johnson HA, Mayo MF, Audette CA, Carrigan CN, LaBelle A, Zukerberg L, Lambert JM, Lutz RJ
MAbs 2014 Mar-Apr;6(2):556-66
PMID 24492307
KMT2A (MLL)-MLLT1 rearrangement in blastic plasmacytoid dendritic cell neoplasm
Yang N, Huh J, Chung WS, Cho MS, Ryu KH, Chung HS
Cancer Genet 2015 Sep;208(9):464-7
PMID 26164398


This paper should be referenced as such :
Aurelia Meloni-Ehrig
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Atlas Genet Cytogenet Oncol Haematol. 2018;22(6):246-251.
Free journal version : [ pdf ]   [ DOI ]
On line version :

Other genes implicated (Data extracted from papers in the Atlas) [ 2 ]

Genes CD2AP TET2

External links

arrayMap (UZH-SIB Zurich)Morph ( 9727/3) -   [auto + random 100 samples .. if exist ]   [tabulated segments]
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Oct 8 16:35:10 CEST 2021

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us